Expert Interviews

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Mike Watson, Vice President of OraNet, unpacks some of the most pressing challenges to clinical research in today’s climate.

Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

At ARVO 2022, Jason S. Slakter, MD, presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

Earlier this year, BioTissue announced the corporate rebrand of its new customer facing entity, including carrying the name over to its surgical business formally known as Amniox Medical. Randy Mansfield, VP of marketing for BioTissue, shares an update at ASCRS 2022.

Dr. Sri Ganesh, MBBS, MS, DNB, chairman and managing director of Nethradhama Hospital Pvt. Ltd, discusses his studies on LENSAR and shares his findings.

Ben Bergo, CEO of Visus Therapeutics, gives a company update on the company's presented phase 2 data, and what's next in the pipeline.

John Berdahl, MD, discusses the technique and benefit of endothelial cell therapy. An early technology, this therapy method allows for up to 100 treatments out of a single human cornea.

Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.

Tom Frinzi, executive chairman of ViaLase, a new company based in Orange County, gives an update on the company, sharing some exciting new things happening.

Orbis International celebrates 40 years of innovation this year, beginning in 1982 with their iconic flying eye hospital. Since their start, Orbis has continued their innovation, working to achieve sustainable and scalable impact in the countries where they work. Doris Macharia, MD, senior vice president of global programs with Orbis, talks with Ophthalmology Times' Sheryl Stevenson, reflecting on the last 40 years and what's to come.

April is Presbyopia Awareness Month. Brieann K. Adair, OD, of NYU Langone Health, speaks with Ophthalmology Times’ Sheryl Stevenson about the importance of Presbyopia awareness, treatment options and more.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Firas M. Rahhal, MD, discusses concerns of using repackaged IV bevacizumab for the treatment of wet AMD.

Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

Dr Lisa Nijm advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.

This new surgical technique offers precision down to the micron level, which is more precise than a surgeon can achieve by themselves.

Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.

Dr. Raymond Douglas discusses the real-world adherence to teprotumumab as a treatment for thyroid eye disease.

Dr. Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Dr Raymond Douglas discusses real-world adherence to teprotumumab as a treatment for thyroid eye disease.